GH1 and intracranial hypertension: The reported AEs were similar overall to AEs observed in previous trials with daily human GH (hGH) treatment, with nasopharyngitis, headache and fatigue as the most frequently occurring AEs for both somapacitan and Norditropin (Table 3); no cases of headache were related to intracranial hypertension as assessed by clinical investigators.